Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Molecular signatures can predict flu vaccine responses in young and old

What factors inhibit strong responses to seasonal flu vaccines in the elderly? Why do anti-flu antibodies last longer after vaccination in some people? Answers are emerging from an Emory University-based systems biology analysis of blood samples from more than 400 volunteers who received seasonal flu vaccines. Bali Pulendran, PhD, led a team of researchers who tracked patterns of gene expression, known as molecular signatures, of strong immune responses in volunteers' blood across five consecutive seasons from 2007 to 2011.

16 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

New rapid test can detect malaria parasites, viruses and biomarkers

Nothing could be simpler: a drop of blood is placed on a special carrier substance; after a wait of a few minutes, the slide is placed on a device that emits polarised light thanks to an inexpensive polarisation filter. It is covered with a lid containing a second polarisation filter, which blocks the light from all materials except crystalline or materials with directional properties.

13 Dec 2015

Abbott, UCSF identify human pegivirus 2 among some patients with hepatitis C

Abbott and University of California San Francisco published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it is found among some patients with hepatitis C (HCV).

12 Dec 2015

Early life exposures to toxic chemicals reduce infants' response to TB vaccine

Early life exposures to toxic chemicals such as PCBs and DDT dampen an infant's response to the tuberculosis vaccine, according to a new study from the University of Rochester Environmental Health Sciences Center.

11 Dec 2015

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Scientists looking at the antiviral mechanisms of two previously identified human monoclonal antibodies have found they potently inhibit chikungunya virus (CHIKV) at multiple stages of infection.

11 Dec 2015

Ajinomoto Althea expands biological drug product manufacturing operations

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).

10 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival.

10 Dec 2015

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option.

From Quest Diagnostics 8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

1 Dec 2015

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs).

1 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

First seasonal influenza vaccine containing adjuvant now approved by FDA

The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.

25 Nov 2015

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

24 Nov 2015

Antibody News and Research

Further Reading

Molecular signatures can predict flu vaccine responses in young and old

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

New rapid test can detect malaria parasites, viruses and biomarkers

Abbott, UCSF identify human pegivirus 2 among some patients with hepatitis C

Early life exposures to toxic chemicals reduce infants' response to TB vaccine

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Ajinomoto Althea expands biological drug product manufacturing operations

Lilly, Merck announce another immuno-oncology collaboration

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

New approaches to treating leukemia, lymphoma and myeloma

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Discovery may lead to potential new therapeutic approach to eradicate blood cancers

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

First seasonal influenza vaccine containing adjuvant now approved by FDA

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

Antibodies eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News